Trial Profile

A investigator initiated clinical study for QRX003 Netherton Syndrome (NS)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 19 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs QRX 003 (Primary)
Indications Netherton Syndrome
Focus Registrational; Therapeutic Use

Most Recent Events

29 Jul 2025 According to a Quoin Pharmaceuticals media release, company anticipates that study will recruit between 12 to 16 subjects, with full recruitment targeted for early to mid Q1 2026.
29 Jul 2025 Planned number of patients changed from 8 to 16.
06 Jan 2025 According to a Quoin Pharmaceuticals media release, company anticipates that clinical data from this study will become a key component of the data package and assembling to support a New Drug Application (NDA) filing for QRX003 as potentially the first approved treatment for Netherton Syndrome. Company look forward to providing additional updates throughout the year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com